GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

Shares of behavioral health company LifeStance Health (NASDAQ:LFST) jumped 11% in the afternoon session after the company ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million ...

U.S. Clinical Nutrition Market Growth BURLINGAME, CA, UNITED STATES, August 8, 2025 /EINPresswire / -- Latest Report, titled U.S ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

London stocks closed little changed on Friday after a week marked by central bank policy moves, shifting economic signals and ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The Food & Beverage sector maintained its leadership position with a 22% share of total ad volumes, followed by the personal ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...